Experts analyze PFAS results in FDA infant formula safety review
The recent government survey of infant formula in the United States has revealed that the majority of the supply is safe for consumption. However, experts and health officials emphasize that there are still measures that can be taken to enhance the safety of a product that is consumed by two-thirds of infants in the country.
A significant finding from the Food and Drug Administration’s testing of 312 formula samples is the presence of per- and polyfluoroalkyl substances (PFAS), also known as “forever chemicals.” Five PFAS were detected in the samples, with PFOS being the most common, found in half of all samples. The majority of samples contained less than 2.9 parts per trillion (ppt) of PFOS.
PFAS exposure has been linked to various health conditions such as higher cholesterol, kidney and testicular cancer, and reduced vaccine efficacy. Experts like toxicologist Alex Bogdan and scientist Katie Pelch have provided insights into the implications of these findings.
Pelch highlighted the importance of manufacturers producing PFAS-free formula and the need for transparency in disclosing which brands may have concerning levels of PFAS. Bogdan emphasized the need for regulatory actions to reduce unnecessary PFAS use and environmental contamination.
There was some confusion regarding the data reporting on PFAS levels, particularly in relation to EPA’s maximum contaminant level (MCL). Bogdan clarified that MCLs are specific to certain PFAS and that the levels detected in infant formula samples were generally low and below health guidance values.
Analysis of the data revealed that powdered soy-based formulas tended to contain short-chain PFAS like PFBA, while dairy-based formulas contained PFOS. Bogdan noted that there was not much overlap in the types of PFAS found in different formulas.
Both experts stressed the importance of reducing PFAS levels in formula and the environment to protect infant health. Pelch called for manufacturers to clean up their supply chains, while Bogdan suggested upstream measures to reduce PFAS in source materials.
In terms of setting a standard for PFAS in formula, Bogdan advocated for the lowest achievable levels, while Pelch suggested aiming for undetectable levels. They also highlighted the need for broader PFAS testing beyond the 30 compounds analyzed in the FDA study.
The potential effects of PFAS on infants include impacts on immune systems, although studies have not shown an increase in disease incidence. Parents are advised to take steps to reduce PFAS exposure, such as avoiding products with stain-resistant treatments and minimizing household dust contamination.
Overall, the public should be aware of the vulnerability of infants to toxic chemical exposure and strive for minimal contamination levels. Ensuring water quality and using appropriate filters can further mitigate PFAS exposure risks. It is crucial to prioritize the health and well-being of the most vulnerable population segment through proactive measures and informed decision-making.
